RxLedger

Valacyclovir (Valacyclovir HCl) — Medicare Part D spending

Multiple manufacturers (17) · Rank #341 by total Part D spend · CMS data year 2023

Medicare Part D spent $121,564,610 on Valacyclovir (Valacyclovir HCl) in 2023, the #341 drug by total Part D spending out of 3,598 drugs. That worked out to about $1.04 per dosage unit, $41 per claim and $88 per beneficiary, across 2,950,170 claims for 1,382,297 beneficiaries. Average spending per dosage unit fell -12.4% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Valacyclovir (Valacyclovir HCl) spending at a glance (2023)

MetricValacyclovir (Valacyclovir HCl)
Total Part D spending (2023)$121,564,610
Total spending (2022)$124,090,097
Year-over-year change in total spending-2.0%
Average spending per dosage unit (2023)$1.04
Change in spend per dosage unit (YoY)-12.4%
Avg annual change per dosage unit (2019-2023 CAGR)-0.5%
Average spending per claim (2023)$41
Average spending per beneficiary (2023)$88
Total claims (2023)2,950,170
Beneficiaries (2023)1,382,297
Total dosage units (2023)122,812,868
Manufacturer(s)Multiple manufacturers (17)
National rank by total spend (of 3,598 drugs)#341

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Valacyclovir (Valacyclovir HCl): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$124,090,097$121,564,610-2.0%
Avg spend per dosage unit$1.18$1.04-12.4%
Avg spend per claim$46$41
Avg spend per beneficiary$98$88
Total claims2,717,6622,950,170
Beneficiaries1,270,2101,382,297

How Valacyclovir compares with nearby drugs

Drugs with total Part D spending closest to Valacyclovir (Valacyclovir HCl):

Valacyclovir (Valacyclovir HCl) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Valacyclovir (Valacyclovir HCl) (this drug, #341)$121,564,610$1.04-12.4%
Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) (#339)$124,346,168$25.46+0.4%
Iclusig (Ponatinib HCl) (#340)$123,338,680$686.96+6.1%
Divalproex Sodium ER (Divalproex Sodium) (#342)$120,375,972$0.93-19.4%
Buprenorphine (#343)$119,900,450$80.07-2.3%
Donepezil HCl (#344)$119,677,286$0.32+2.6%

Frequently asked questions

How much does Medicare Part D spend on Valacyclovir?

Medicare Part D spent $121,564,610 on Valacyclovir (Valacyclovir HCl) in 2023 (the latest CMS data year), across 2,950,170 claims for 1,382,297 beneficiaries. That ranks #341 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Valacyclovir?

In 2023, the weighted average Medicare Part D spending per dosage unit for Valacyclovir (Valacyclovir HCl) was $1.04. Compared with 2022 it fell -12.4%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Valacyclovir?

CMS attributes Valacyclovir (Valacyclovir HCl) to Multiple manufacturers (17) in the 2023 Part D spending file. Average spending per claim was $41 and per beneficiary $88.

Is the Valacyclovir figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20